Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 4;13(5):981-985.
doi: 10.1080/21645515.2017.1264795. Epub 2017 Mar 8.

Persistence of immunity 18-19 years after vaccination against hepatitis B in 2 cohorts of vaccinees primed as infants or as adolescents in Italy

Luisa Romanò  1 , Cristina Galli  1 , Catia Tagliacarne  1 , Maria Elena Tosti  2 , Claudio Velati  3 , Laura Fomiatti  4 , Maria Chironna  5 , Rosa Cristina Coppola  6 , Mario Cuccia  7 , Rossana Mangione  8 , Fosca Marrone  9 , Francesco Saverio Negrone  10 , Antonino Parlato  11 , Carla Maria Zotti  12 , Alfonso Mele  2 , Alessandro Remo Zanetti  1 ; Study Group
Affiliations

Persistence of immunity 18-19 years after vaccination against hepatitis B in 2 cohorts of vaccinees primed as infants or as adolescents in Italy

Luisa Romanò et al. Hum Vaccin Immunother. .

Abstract

This study was aimed at assessing the anti-HBs persistence and immune memory 18-19 y after vaccination against hepatitis B in healthy individuals primed as infants or adolescents. We enrolled 405 teenagers (Group A) vaccinated as infants, and 409 young adults (Group B) vaccinated as adolescents. All vaccinees were tested for anti-HBs and anti-HBc antibodies; those found anti-HBc positive were further tested for HBsAg and HBV DNA. Eight individuals belonging to Group B were positive for anti-HBc alone, and were excluded from analysis. Individuals with anti-HBs concentration ≥ 10 mIU/ml were considered protected while those with anti-HBs concentration <10 mIU/ml were offered a booster dose and re-tested 2 weeks later. Overall, 67.9% individuals showed anti-HBs concentrations ≥ 10 mIU/ml (48.9% in Group A vs 87.0% in Group B, p < 0.001). The antibody geometric mean concentration (GMC) was higher in Group B than in Group A (102.5 mIU/ml vs 6.9 mIU/ml; p < 0.001). When boosted, 94.2% of vaccinees with anti-HBs <10 mIU/ml belonging to Group A and 94.7% to Group B showed an anamnestic response. Post-booster GMCs were similar in both groups (477.9 mIU/ml for Group A vs 710.0 mIU/ml for Group B, p = n.s.). Strong immunological memory persists for at least 18-19 y after immunization of infants or adolescents with a primary course of vaccination. Thus, booster doses are not needed at this time, but additional follow up is required to assess the long-life longevity of protection.

Keywords: HBV; hepatitis B; immune memory; long-term immunity; vaccination.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study profile.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) Available from http://www.who.int/mediacentre/factsheets/fs204/en/ (last access March7, 2017).
    1. Zanetti AR, Tanzi E, L Romanò, Grappasonni I. Vaccination against hepatitis B: the Italian strategy. Vaccine 1993; 11:521-4; PMID:8488702; http://dx.doi.org/10.1016/0264-410X(93)90222-J - DOI - PubMed
    1. Ministero della Salute Available from http://www.salute.gov.it/imgs/C_17_tavole_20_allegati_iitemAllegati_0_fi... (last access March7, 2017).
    1. Assad S, Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 1999; 18:57-67; PMID:10501235; http://dx.doi.org/10.1016/S0264-410X(99)00179-6 - DOI - PubMed
    1. Venters C, Graham W, Cassidy W. Recombivax-HB: perspectives past, present and future. Expert Rev Vaccines 2004; 3:119-29; PMID:15056038; http://dx.doi.org/10.1586/14760584.3.2.119 - DOI - PubMed

Publication types

Substances

LinkOut - more resources